Compound Information | SONAR Target prediction | Name: | SIBUTRAMINE HYDROCHLORIDE | Unique Identifier: | SPE01505210 | MolClass: | Checkout models in ver1.5 and ver1.0 | Molecular Formula: | | Molecular Weight: | 289.094 g/mol | X log p: | 8.664 (online calculus) | Lipinksi Failures | 1 | TPSA | 3.24 | Hydrogen Bond Donor Count: | 0 | Hydrogen Bond Acceptors Count: | 1 | Rotatable Bond Count: | 5 | Canonical Smiles: | Cl.CC(C)CC(N(C)C)C1(CCC1)c1ccc(Cl)cc1 | Source: | synthetic | Therapeutics: | anorexic, antidepressant, uptake inhibitor (5HT, norepinephrine, dopamine) | Generic_name: | Sibutramine | Chemical_iupac_name: | 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethyl-butan-1-amine | Drug_type: | Approved Drug | Pharmgkb_id: | PA451344 | Kegg_compound_id: | C07247 | Drugbank_id: | APRD00456 | Melting_point: | 191-192 oC | H2o_solubility: | 2.9 mg/mL (in pH 5.2 water) | Logp: | 5.906 | Cas_registry_number: | 106650-56-0 | Drug_category: | Appetite Depressants; Antidepressants; Anorexigenic Agents; Stimulants; ATC:A08AA10 | Indication: | For the treatment of obesity. | Pharmacology: | Sibutramine is an orally administered agent for the treatment of obesity. Sibutramine exerts its pharmacological actions predominantly via its secondary (M1) and primary (M2) amine metabolites. The parent compound, sibutramine, is a potent inhibitor of serotonin and norepinephrine reuptake in vivo, but not in vitro. However, metabolites M1 and M2 inhibit the reuptake of these neurotransmitters both in vitro and in vivo. In human brain tissue, M1 and M2 also inhibit dopamine reuptake in vitro, but with ~3-fold lower potency than for the reuptake inhibition of serotonin or norepinephrine. Sibutramine, M1 and M2 exhibit no evidence of anticholinergic or antihistaminergic actions. In addition, receptor binding profiles show that sibutramine, M1 and M2 have low affinity for serotonin (5-HT1, 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C), norepinephrine (b, b1, b3, a1 and a2), dopamine (D1 and D2), benzodiazepine, and glutamate (NMDA) receptors. These compounds also lack monoamine oxidase inhibitory activity in vitro and in vivo. | Mechanism_of_action: | Sibutramine produces its therapeutic effects by norepinephrine (NE), serotonin reuptake (5-hydroxytryptamine, 5-HT) and dopamine reuptake inhibition. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines. | Organisms_affected: | Humans and other mammals |
Species: |
4932 |
Condition: |
BCK1 |
Replicates: |
2 |
Raw OD Value: r im |
0.7261±0.0362746 |
Normalized OD Score: sc h |
1.0054±0.00399963 |
Z-Score: |
0.2655±0.0828543 |
p-Value: |
0.79101 |
Z-Factor: |
-3.68138 |
Fitness Defect: |
0.2344 |
Bioactivity Statement: |
Nonactive |
Experimental Conditions | | Library: | SPECMTS3 | Plate Number and Position: | 1|B8 | Drug Concentration: | 50.00 nM | OD Absorbance: | 600 nm | Robot Temperature: | 23.10 Celcius | Date: | 2008-05-14 YYYY-MM-DD | Plate CH Control (+): | 0.04005±0.00051 | Plate DMSO Control (-): | 0.6933750000000001±0.01623 | Plate Z-Factor: | 0.9300 |
| png ps pdf |
5210 |
1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethyl-butan-1-amine |
64764 |
1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethyl-butan-1-amine hydrochloride |
64765 |
1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethyl-butan-1-amine hydrate hydrochloride |
667542 |
(1R)-1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethyl-butan-1-amine |
937011 |
(1S)-1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethyl-butan-1-amine |
4978638 |
[1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl-butyl]-dimethyl-azanium |
internal high similarity DBLink | Rows returned: 0 | |
nonactive | Cluster 2147 | Additional Members: 1 | Rows returned: 0 | |
|